The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03525600




Registration number
NCT03525600
Ethics application status
Date submitted
20/04/2018
Date registered
15/05/2018
Date last updated
2/07/2020

Titles & IDs
Public title
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Scientific title
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Secondary ID [1] 0 0
APL2-303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Geographic Atrophy 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - APL-2
Treatment: Drugs - APL-2
Other interventions - Sham Procedure
Other interventions - Sham Procedure

Experimental: APL-2 15mg 0.1 mL monthly for 24 months - A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month

Experimental: APL-2 15mg 0.1 mL EOM for 24 months - A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month

Experimental: Sham Procedure Monthly for 24 months - Sham Procedure for 24 months

Experimental: Sham Procedure Every Other Month for 24 months - Sham Procedure every other month for 24 months


Treatment: Drugs: APL-2
Complement (C3) Inhibitor

Treatment: Drugs: APL-2
Complement (C3) Inhibitor

Other interventions: Sham Procedure
Subjects will receive a Sham procedure every month

Other interventions: Sham Procedure
Subjects will receive a Sham procedure every other month

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to Month 12 in total area of GA Lesion(s) in the study eye (in mm2) as Measured by Fundus Autofluorescence (FAF)
Timepoint [1] 0 0
Baseline, 12 months
Secondary outcome [1] 0 0
Incidence and severity of ocular and systemic treatment-emergent adverse events.
Timepoint [1] 0 0
30 months

Eligibility
Key inclusion criteria
The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria,
the eye with the worst visual acuity at the screening visit will be designated as the study
eye. If both eyes have the same visual acuity, the right eye will be selected as the study
eye.

Ocular- specific inclusion criteria apply to the study eye only, unless otherwise
specified.

- Age = 60 years.

- Normal Luminance best corrected visual acuity of 24 letters or better using Early
Treatment Diabetic Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen
equivalent).

- Clinical diagnosis of GA of the macula secondary to AMD as determined by the
Investigator and confirmed by the Reading Center.

- The GA lesion must meet the following criteria as determined by the central reading
center's assessment of Fundus Autofluorescence (FAF) imaging at screening:

- Total GA area must be = 2.5 and = 17.5 mm2 (1 and 7 disk areas [DA] respectively)

- If GA is multifocal, at least one focal lesion must be = 1.25 mm2 (0.5 DA), with
the overall aggregate area of GA as specified above in 4a.

- The entire GA lesion must be completely visualized on the macula centered image
and must be able to be imaged in its entirety and not contiguous with any areas
of peripapillary atrophy.

- Presence of any pattern of hyperautofluorescence in the junctional zone of GA.
Absence of hyperautofluorescence (i.e. pattern = none) is exclusionary.

- Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit
the collection of good quality images as determined by the Investigator.

- Female subjects must be:

- Women of non-child-bearing potential (WONCBP), or

- Women of child-bearing potential (WOCBP) with a negative serum pregnancy test at
screening and must agree to use protocol defined methods of contraception for the
duration of the study and refrain from breastfeeding for the duration of the
study.

- Males with female partners of child-bearing potential must agree to use protocol
defined methods of contraception and agree to refrain from donating sperm for the
duration of the study.

- Willing and able to give informed consent and to comply with the study procedures and
assessments.
Minimum age
60 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Ocular specific exclusion criteria apply to the study eye only, unless otherwise specified.

- GA secondary to a condition other than AMD such as Stargardt disease, cone rod
dystrophy or toxic maculopathies like plaquenil maculopathy in either eye.

- Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or
an axial length >26 mm.

- Any history or active choroidal neovascularization (CNV), associated with AMD or any
other cause, including any evidence of retinal pigment epithelium rips or evidence of
neovascularization anywhere based on SD-OCT imaging and/or fluorescein angiography as
assessed by the Reading Center.

- Presence of an active ocular disease that in the opinion of the Investigator
compromises or confounds visual function, including but not limited to, uveitis, other
macular diseases (e.g. clinically significant epiretinal membrane (ERM), full
thickness macular hole or uncontrolled glaucoma/ocular hypertension. Benign conditions
in the opinion of the investigator such as peripheral retina dystrophy are not
exclusionary).

- Intraocular surgery (including lens replacement surgery) within 3 months prior to
randomization.

- History of laser therapy in the macular region.

- Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for
posterior capsule opacification done at least 60 days prior to screening is not
exclusionary.

- Any ocular condition other than GA secondary to AMD that may require surgery or
medical intervention during the study period or, in the opinion of the Investigator,
could compromise visual function during the study period.

- Any contraindication to IVT injection including current ocular or periocular
infection.

- History of prior intravitreal injection.

- Prior participation in another interventional clinical study for intravitreal
therapies in either eye (including subjects receiving sham).

- Prior participation in another interventional clinical study for geographic atrophy in
either eye including investigational oral medication and placebo.

- Participation in any systemic experimental treatment or any other systemic
investigational new drug within 6 weeks or 5 half-lives of the active ingredient
(whichever is longer) prior to the start of study treatment. Note: clinical trials
solely involving observation, over-the-counter vitamins, supplements, or diets are not
exclusionary.

- Medical or psychiatric conditions that, in the opinion of the investigator, make
consistent follow-up over the 24-month treatment period unlikely, or would make the
subject an unsafe study candidate.

- Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the
opinion of the Investigator is clinically significant and not suitable for study
participation.

- Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to
APL-2 or any of the excipients in APL-2 solution.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Sydney Retina - Sydney
Recruitment hospital [2] 0 0
Centre for Eye Research Australia - East Melbourne
Recruitment hospital [3] 0 0
Retina and Eye Consultants - Hurstville
Recruitment postcode(s) [1] 0 0
2000 - Sydney
Recruitment postcode(s) [2] 0 0
3002 - East Melbourne
Recruitment postcode(s) [3] 0 0
NSW 2220 - Hurstville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
South Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Capital Federal
Country [26] 0 0
Argentina
State/province [26] 0 0
Corrientes
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Córdoba
Country [30] 0 0
Argentina
State/province [30] 0 0
Mendoza
Country [31] 0 0
Argentina
State/province [31] 0 0
Rosario
Country [32] 0 0
Brazil
State/province [32] 0 0
Espirito Santo
Country [33] 0 0
Brazil
State/province [33] 0 0
Sao Paulo
Country [34] 0 0
Brazil
State/province [34] 0 0
Vila Clementino
Country [35] 0 0
Brazil
State/province [35] 0 0
Belo Horizonte
Country [36] 0 0
Brazil
State/province [36] 0 0
Porto Alegre
Country [37] 0 0
Brazil
State/province [37] 0 0
São Paulo
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Ottawa
Country [40] 0 0
Czechia
State/province [40] 0 0
Ostrava-Poruba
Country [41] 0 0
Czechia
State/province [41] 0 0
Pardubice
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha
Country [43] 0 0
Czechia
State/province [43] 0 0
Vinohrady
Country [44] 0 0
France
State/province [44] 0 0
Créteil
Country [45] 0 0
France
State/province [45] 0 0
Lyon
Country [46] 0 0
France
State/province [46] 0 0
Marseille
Country [47] 0 0
France
State/province [47] 0 0
Nantes
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
France
State/province [49] 0 0
Saint-Cyr-sur-Loire
Country [50] 0 0
France
State/province [50] 0 0
Strasbourg
Country [51] 0 0
Germany
State/province [51] 0 0
Bonn
Country [52] 0 0
Germany
State/province [52] 0 0
Cologne
Country [53] 0 0
Germany
State/province [53] 0 0
Ludwigshafen
Country [54] 0 0
Germany
State/province [54] 0 0
München
Country [55] 0 0
Germany
State/province [55] 0 0
Regensburg
Country [56] 0 0
Germany
State/province [56] 0 0
Würzburg
Country [57] 0 0
Israel
State/province [57] 0 0
Be'er Ya'aqov
Country [58] 0 0
Israel
State/province [58] 0 0
Haifa
Country [59] 0 0
Israel
State/province [59] 0 0
Kfar Saba
Country [60] 0 0
Israel
State/province [60] 0 0
Petah tikva
Country [61] 0 0
Israel
State/province [61] 0 0
Re?ovot
Country [62] 0 0
Israel
State/province [62] 0 0
Tel Aviv
Country [63] 0 0
Italy
State/province [63] 0 0
Milano
Country [64] 0 0
New Zealand
State/province [64] 0 0
Auckland
Country [65] 0 0
New Zealand
State/province [65] 0 0
Hamilton
Country [66] 0 0
Poland
State/province [66] 0 0
Bydgoszcz
Country [67] 0 0
Poland
State/province [67] 0 0
Olsztyn
Country [68] 0 0
Poland
State/province [68] 0 0
Tarnow
Country [69] 0 0
Poland
State/province [69] 0 0
Lódz
Country [70] 0 0
Puerto Rico
State/province [70] 0 0
Arecibo
Country [71] 0 0
Spain
State/province [71] 0 0
Barcelona
Country [72] 0 0
Spain
State/province [72] 0 0
Santiago De Compostela
Country [73] 0 0
Spain
State/province [73] 0 0
Valladolid
Country [74] 0 0
United Kingdom
State/province [74] 0 0
England
Country [75] 0 0
United Kingdom
State/province [75] 0 0
West Yorkshire
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Bristol
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Leeds
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Leicester
Country [79] 0 0
United Kingdom
State/province [79] 0 0
London
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Oxford
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Salisbury
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Sunderland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Apellis Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection
controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in
subjects with GA secondary to AMD.
Trial website
https://clinicaltrials.gov/show/NCT03525600
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Apellis Clinical Trial Information Line
Address 0 0
Country 0 0
Phone 0 0
1-833-284-6361
Fax 0 0
Email 0 0
clinicaltrials@apellis.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03525600